TickerTalks
Browse all tickers →
TickerTalks›$TENX
TETENX

Tenax Therapeutics, Inc.

$TENX·$48M·Biotechnology·Healthcare
$1.85+2.2%YTD-84.5%1Y-74.6%
Price updated 12h ago·X counts updated 1d ago
TETENX
$TENXTenax Therapeutics, Inc.
$1.85+2.21%25 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $TENX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

25X posts · last 7 days
Sep 11Sep 27
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $TENX's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-09-13

Tenax Therapeutics sentiment is bullish after ADAR1 Capital doubled down post-Phase 3 miss, buying another ~770K shares for $1.38M around $1.79-$1.80/share plus $1.6M more (fourth buy in days). Bulls model $3.37 cash per share against $1.90 stock and speculate on a $7.30 proposed acquisition announcement at the Sept 9 conference.

Read what X is saying about $TENX

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $TENX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-09-28

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Tenax Therapeutics is down 85% YTD post Phase 3 miss — ADAR1 Capital doubled down for $3M+ across three September buys plus director cluster with $7.30 acquisition speculation.

Tenax Therapeutics is a clinical-stage cardiovascular-and-pulmonary franchise (TNX-103 levosimendan for pulmonary hypertension in HFpEF, TNX-201 imatinib for PAH) — a broken-story micro-cap that just triggered a distinct insider-cluster event after the Phase 3 miss. The stock is at 3% of the 52-week range.

  • The insider cluster is exceptional: ADAR1 Capital bought 1.67M shares across Aug 31-Sept 3 for ~$3M at $1.78-$1.80, plus director Doogan bought 53K for $102K and CEO Giordano bought 10.85K shares — three distinct buyers in 30 days is a real conviction signal.
  • The Aug 10 TNX-103 Phase 3 LEVEL miss is the primary tape event: pulmonary hypertension in HFpEF failed the pivotal, though the Aug 29 ESC Congress late-breaker presentation kept the science visible.
  • The Aug 19 Levi & Korsinsky securities investigation notice is the legal overhang — real, though the size and distinct-buyer conviction signal offset (X posters model $3.37 cash per share vs $1.90 stock plus $7.30 acquisition-announcement speculation).

Q3 earnings on Nov 11 is the reset — a firm strategic-alternatives-review commentary or an acquisition confirmation restarts the story; another quarter of program-only commentary and the tape stays coiled near lows.

Agrees with X sentimentX bulls correctly identify ADAR1 Capital's ~$3M cluster buys post-Phase 3 miss and the $3.37 cash per share vs $1.90 stock framing — every claim aligns with the Form 4 data and the insider-cluster metadata. The $7.30 acquisition speculation is unconfirmed but the underlying conviction signal is real. Partial agreement.

What to watch: Q3 earnings on Nov 11 — a firm strategic-alternatives-review commentary or an acquisition confirmation restarts the story; another quarter of program-only commentary and the tape stays coiled near lows.

On the calendar: 2026-11-11 — Q3 earnings

adar1 3m cluster buyphase3 level misscash above stock price

Read the AI verdict on $TENX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage cardiovascular pharma developing levosimendan for heart failure and other acute cardiac conditions in the US and Canada.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $TENX.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $TENX

Neutral — Clinical-stage cardiovascular pharma developing levosimendan for heart failure and other acute cardiac conditions in the US and Canada.

Top industry ETF

$IBBiShares Biotechnology ETF
+24.2%YTD
+48.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-60.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-13.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-61.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 31, 2026$-0.35$-0.38+8.2%
Q1 2026May 12, 2026$-0.35$-0.40+12.5%
Q4 2025Mar 10, 2026$-0.38$-1.26+69.8%
Q3 2025Nov 12, 2025$-0.40$-1.33+69.9%
Next earningsWed, Nov 11·consensus EPS $-0.35

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.35$-14.2M
Q1 FY26$0———$-0.35$-9.3M
Q4 FY25$0———$-0.39$-13.4M
Q3 FY25$0———$-0.40$-9.2M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$4.2M$4.2M – $4.2M-$1.45-$1.60 – -$1.219
FY27$12.9M$12.9M – $12.9M-$1.45-$1.56 – -$1.329
FY28$26.7M$26.7M – $26.7M-$1.72-$2.15 – -$1.249
FY29$51.9M$51.9M – $51.9M-$1.55-$1.55 – -$1.554
FY30$137.6M$137.6M – $137.6M-$1.07-$1.07 – -$1.074

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.3%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-67.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-83.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 26.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today8.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.935-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Cluster buy4 insiders bought shares in the last 30 days.

Recent transactions

BuySep 16Declan DooganDirector53.0K sh$102KBuySep 15Giordano Christopher ThomasCEO4.8K sh$9KBuySep 11Giordano Christopher ThomasCEO6.0K sh$11KBuySep 11Thomas R StaabCFO5.7K sh$11KBuySep 3Adar1 Capital Management, Llc10% owner900.0K sh$1.6MBuySep 2Adar1 Capital Management, Llc10% owner187.7K sh$338KBuySep 1Adar1 Capital Management, Llc10% owner179.1K sh$322KBuyAug 31Adar1 Capital Management, Llc10% owner403.6K sh$723KBuyAug 24Adar1 Capital Management, Llc10% owner107.4K sh$188KBuyAug 21Adar1 Capital Management, Llc10% owner716.4K sh$1.3M
1–10 of 11
+ 2 other (1 exempt · 1 award) in window

See when $TENX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 98-K — Item 7.01: Press release / Reg FD
AI summary

Tenax Therapeutics presented at the 2026 Cantor Global Healthcare Conference on September 9, 2026 at 8:35 AM ET, using a condensed corporate presentation. The full presentation was published on the company's website and furnished as Exhibit 99.1. This is a routine Reg FD investor conference disclosure for the cardiovascular critical care biotech.

3New insider — initial holdingsAug 243
AI summary

A new insider at Tenax Therapeutics (TENX) filed Form 3 reporting indirect beneficial ownership of 3,827,951 shares of common stock through a footnoted ownership structure. This is a significant initial ownership disclosure for a micro-cap biotech. Material initial insider ownership report representing a substantial position relative to a small-cap company's outstanding share count.

SC 13D/AActivist amendmentJul 31SC 13D/A
AI summary

is deemed to own in the aggregate and on a beneficial ownersh amended its 13D filing disclosing a beneficial ownership position of 4.32% in TENX (TENX) as of 2026-07-31. This is a material ownership disclosure indicating significant shareholder interest that may signal activist or strategic intent. Investors should monitor for further 13D amendments, which could indicate evolving positions or demands on management.

8-KMaterial agreementJun 308-K — Item 1.01: Material agreement
AI summary

Tenax Therapeutics, Inc. (TENX) entered into Supply Agreement As previously disclosed, pursuant to the License Agreement (as define with a counterparty on 2026-06-30, involving undisclosed consideration. closed, pursuant to the License Agreement (as defined below) between Tenax Thera. This is a material definitive agreement (Item 1.01) requiring immediate disclosure under SEC rules. Investors should review the agreement terms for financial obligations, dilution, or strategic implications.

8-KOfficer or director changeJun 298-K — Item 5.02: Officer or director change · Item 8.01: Other event
AI summary

Tenax Therapeutics, Inc. (TENX) disclosed an officer or director change (Item 5.02) on 2026-06-29. Also disclosed: Item 8.01. Details: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Executive transitions are administrative disclosures; materiality depends on the seniority of the affected position. No new financial terms were disclosed in this filing.

8-KShareholder voteJun 48-K — Item 5.07: Shareholder vote
3New insider — initial holdingsMay 133
8-KOfficer or director changeApr 228-K — Item 5.02: Officer or director change · Item 8.01: Other event
+ 43 other (33 13Gs · 2 routine 8-Ks · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Insider Buying: Tenax Therapeutics (NASDAQ:TENX) Director Buys $101,760.00 in Stockdefenseworld.net·9d agoTenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conferenceglobenewswire.com·28d agoTenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026globenewswire.com·31d agoTenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinskygurufocus.com·41d agoTenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinskyprnewswire.com·41d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$VKTX$MRNA$RARE$NWBO$AURA$ARCT$IBRX$NKTR
Voices on X · last 7 days

No standout posts about $TENX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport